The Manufacturers Life Insurance Company lifted its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 5.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,059,100 shares of the specialty pharmaceutical company’s stock after acquiring an additional 50,529 shares during the quarter. The Manufacturers Life Insurance Company owned 0.30% of Valeant Pharmaceuticals International worth $18,376,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Harbor Advisors LLC purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth $110,000. NEXT Financial Group Inc increased its position in shares of Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after acquiring an additional 600 shares during the period. Financial Architects Inc increased its position in shares of Valeant Pharmaceuticals International by 10.5% during the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock worth $183,000 after acquiring an additional 1,000 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after acquiring an additional 2,763 shares during the period. Finally, IPG Investment Advisors LLC purchased a new stake in shares of Valeant Pharmaceuticals International during the second quarter worth $203,000. 50.44% of the stock is currently owned by institutional investors and hedge funds.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the transaction, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 5.87% of the stock is owned by corporate insiders.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 12.92 on Tuesday. The stock’s 50 day moving average is $13.96 and its 200 day moving average is $13.57. Valeant Pharmaceuticals International, Inc. has a 52 week low of $8.31 and a 52 week high of $24.30. The firm’s market cap is $4.50 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter in the prior year, the firm earned ($0.88) EPS. The company’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, equities research analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/10/17/the-manufacturers-life-insurance-company-buys-50529-shares-of-valeant-pharmaceuticals-international-inc-vrx.html.

A number of analysts have recently weighed in on the company. Vetr lowered Valeant Pharmaceuticals International from a “strong-buy” rating to a “hold” rating and set a $14.26 price objective on the stock. in a research report on Friday. Zacks Investment Research lowered Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Thursday, October 12th. Deutsche Bank AG reissued a “hold” rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals International in a report on Monday, October 9th. HC Wainwright reissued a “hold” rating and issued a $17.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, October 4th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $16.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, October 3rd. Five research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $17.71.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.